

Manufacturer's Information Test No. 24-5840/1/2: DNA Database - Saliva

Each sample set consisted of a collection of known buccal cells from three individuals (Items 1-3), provided on either FTA[™] Indicating Micro Cards, Bode Buccal® DNA Collectors, or Puritan® Cap-Shure® swabs. Participants were asked to analyze these items using their existing protocols.

SAMPLE PREPARATION: All substrates were prepared from human buccal cheek cells suspended in sterile phosphate-buffered saline solution. The FTATM Indicating Micro Cards were spotted with 120 μ L of the cell suspension, the Bode Buccal® DNA Collectors were spotted with 200 μ L of the cell suspension, and the Puritan® Cap-Shure® swabs were spotted with 125 μ L of the cell suspension. Item 1 was created using a male donor. Item 2 and Item 3 were created using two different female donors. The items were prepared at separate times and were packaged once they were thoroughly dried. Completed sample sets were stored at -20°C until shipment on January 30, 2024.

SAMPLE SET ASSEMBLY: For each sample set, all Items (1-3) of the same substrate type were packaged into separate envelopes and then placed together in a pre-labeled sample set envelope and sealed. The sealed sample set envelopes were then packaged in pre-labeled heat seal envelopes and sealed. This process was repeated until all of the sample sets were prepared.

VERIFICATION: Predistribution results were consistent with each other and the manufacturer's preparation information. Consistent allelic results were reported for all STR and YSTR loci across all three substrates.

Key to Test Substrates

5840 - FTA[™] Indicating Micro Cards
5841 - Bode Buccal® DNA Collectors
5842 - Puritan® Cap-Shure® Swabs

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the results that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.

Manufacturer's Information, continued Test No. 24-5840/1/2: DNA Database - Saliva

Amelogenin and STR Results												
	Results cor	npiled from predis	tribution laborator	ries and a consensu	ıs of at least 10 part	icipants.						
ltem	D1S1656 D2S133		D2S441	D3S1358	D5\$818	D6S1043						
	D7S820	D8S1179	D10S1248	D12S391	D13S317	D16S539						
	D18S51	D19S433	D21S11	D22S1045	Amelogenin	CSF1PO						
	FGA	Penta D	Penta E	SE33	TH01	ΤΡΟΧ						
	vWA	DY\$391	DY\$570	DYS576	Y Indel							
1	13,17.3	17,25	11,11	16,17	10,12	*						
	9,10	10,15	15,17	19,20	12,12	12,13						
	13,14	15,16.2	29,30	11,15	X,Y	10,11						
	20,21	9,13	10,12	17,21.2	8,9.3	8,8						
	17,19	10	17	19	2							
2	17,17	20,24	12,14	17,18	11,11	*						
	10,10	10,12	13,15	15,18	8,12	12,13						
	15,17	14,14	28,32.2	16,16	X,X	10,11						
	19,21.2	9,13	5,18	24.2,31.2	6,7	8,10						
	14,17	NM	NM	NM	NM							
3	15,16	20,21	10,11	15 <i>,</i> 17	12,13	*						
	11,12	14,14	13,17	15,22	12,13	12,13						
_	14,15	13,15	28,31	11,11	X,X	11,11						
	21,26	11,11	7,11	24.2,27.2	6,9.3	8,8						
_	18,18	NM	ŇM	NM	ŇM							

YSTR Results

Results compiled from predistribution laboratories and a consensus of at least 10 participants.										
ltem	DYF38751	DYS19	DYS385	DYS389-I	DYS389-II	DYS390	DYS391	DYS392	DYS393	
	DYS437	DYS438	DYS439	DYS448	DYS449	DYS456	DYS458	DYS460	DYS481	
	DY\$518	DYS533	DYS549	DYS570	DYS576	DYS627	DYS635	DYS643	YGATAH4	
1	35,38	16	11,15	13	29	24	10	13	13	
	14	12	12	19	30	15	17	11	22	
	39	12	13	17	19	21	24	10	12	

* A consensus was not achieved for the loci indicated.

NM - Non-Male profile, YSTR results not expected.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the results that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.